Loading...
•
Jun 30, 2021
Axon Q2 2021 Earnings Report
Axon's Q2 2021 performance was strong, with significant revenue growth and increased international presence.
Key Takeaways
Axon Enterprise reported a strong Q2 2021, with revenue up 55% year-over-year to $219 million. International revenue grew 60%, and the company raised its full-year outlook. The company's performance was driven by increasing global demand for its life-saving technology, including TASER devices and body cameras.
Revenue of $219 million grew 55% year over year.
International revenue grew 60% year over year and international bookings nearly tripled versus Q2 2020.
Annual Recurring Revenue (ARR) grew 42% year over year to $260 million.
Total company future contracted revenue surpassed $2 billion.
Axon
Axon
Axon Revenue by Segment
Revenue by Segment
TASER Revenue
CapyFin.comSoftware & Services Revenue
CapyFin.com Forward Guidance
Axon expects to achieve revenue in the range of $825 million to $850 million and Adjusted EBITDA to a range of $155 million to $160 million for 2021.
Positive Outlook
- Revenue in the range of $825 million to $850 million is expected.
- Adjusted EBITDA is expected to be in the range of $155 million to $160 million.
- The company intends to continue investing for growth.
- The company's investments are yielding results ahead of expectations.
- The business in 2022 includes approximately $960 million in revenue.
Challenges Ahead
- Stock-based compensation expense is expected to be more than $275 million for the full year.
- Forecasting stock-based compensation expense is inherently difficult.
- Expectations for capital expenditures of approximately $65 million to $70 million in 2021 are unchanged.
- Forward-looking statements are subject to risks and uncertainties.
- The company is exposed to cancellations of government contracts due to appropriation clauses.
Revenue & Expenses
Visualization of income flow from segment revenue to net income